Home Products Building Blocks Functional Group CS 0114507

CS-0114507

Bromoacetamido-PEG9-ethylcarbamoyl-C12-Boc

Name: Bromoacetamido-PEG9-ethylcarbamoyl-C12-Boc | ChemScene | Chemikart
Brand: Chemikart
Price: 1 inr
Availability: InStock

Manufacturer: ChemScene

CAS Number: None

The price for this product is unavailable. Please request a quote

Purity

98%

MDL No

None

Storage

Sealed in dry,2-8℃

Shipping

Room temperature in continental US; may vary elsewhere.

Molecular Formula

C40H77BrN2O13

Molecular Weight

873.95

Synonyms

None

SMILES

BrCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CCCCCCCCCCCCC(OC(C)(C)C)=O)=O)=O

Tpsa

167.57

Logp

4.786

H Acceptors

H Donors

Rotatable Bonds

Other Options

Product Name	Manufacturer	Price Range
(Z)2S,4R-Sacubitril	--	₹ 57,850.00 - ₹ 1,78,000.00
(R,Z)-tert-Butyl (1-(7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate Linagliptin Impurity	--	₹ 34,265.00
(R)-7-(But-2-yn-1-yl)-8-(3-hydroxypiperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione Linagliptin Impurity	--	₹ 13,706.00
Ethyl 2-((3,5-dichloropyridin-2-yl)amino)-2-oxoacetate Edoxaban Impurity	--	₹ 13,706.00
Ethyl 2-((4-Chloropyridin-2-yl)amino)-2-oxoacetate Edoxaban Impurity	--	₹ 13,706.00
Ethyl 2-((6-chloropyridin-2-yl)amino)-2-oxoacetate Edoxaban Impurity	--	₹ 13,706.00
N1-(5-Chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(methylsulfonamido)cyclohexyl)oxalamide Edoxaban Impurity	--	₹ 13,706.00
Isopropyl 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonate Palbociclib Impurity	--	₹ 41,118.00
Methyl 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonate Palbociclib Impurity	--	₹ 20,559.00
N,N'-((1S,2R,4S)-4-(Dimethylcarbamoyl)cyclohexane-1,2-diyl)bis(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide) Edoxaban Impurity	--	₹ 13,706.00

...

SAFETY INFORMATION

Pictograms

N/A

Signal Word

N/A

UN Number

N/A

Class

N/A

Packing Group

N/A

Hazard Statements

N/A

Precautionary Statements

N/A